Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects

Microvascular Research

Volumn 79, Issue 2, 2010, Pages 144-149

  Derosa, Giuseppe ^a   D'Angelo, Angela ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Fogari, Elena ^a   Gravina, Alessia ^a   Mereu, Roberto ^a   Palumbo, Ilaria ^a   Maffioli, Pamela ^a   Randazzo, Sabrina ^a   Cicero, Arrigo F G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Endothelial stress; Metalloproteinases; OGTT; Type 2 diabetes mellitus; Vascular remodelling

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BIGUANIDE; BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; GLITAZONE DERIVATIVE; GLUCOSE; NITRATE; NITRITE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIET; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NITRATES; NITRITES; OVERWEIGHT; POSTPRANDIAL PERIOD;

EID: 76749107411     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.01.002     Document Type: Article

References (33)

1. American Diabetes Association. Screening for diabetes (Position Statement). Diabetes Care 24 1 (2001) S21-S24
2. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 30 (2007) S4-S41
3. Asadollahi K., Beeching N., and Gill G. Hyperglycaemia and mortality. J. R. Soc. Med. 100 11 (2007) 503-507
4. Bartnik M., Norhammar A., and Rydén L. Hyperglycaemia and cardiovascular disease. J. Intern. Med. 262 2 (2007) 145-156
5. Bell D.S., O'Keefe J.H., and Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?. Endocr. Pract. 14 1 (2008) 112-124
6. Berg A.H., Combs T.P., and Scherer P.E. ARCP 30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 13 2 (2002) 84-89
7. Blüher M., et al. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia 45 2 (2002) 210-216
8. Cicero G., et al. Vascular remodelling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium 14 4-5 (2007) 193-198
9. Derosa G., et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13 3 (2006) 227-231
10. Derosa G., et al. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 14 1 (2007) 45-51
11. Derosa G., et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab. 33 2 (2007) 129-134
12. Dollery C.M., McEwan J.R., and Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77 (1995) 863-868
13. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet. Med. 16 (1999) 716-730
14. Fujimoto N., et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin. Chim. Acta 221 1-2 (1993) 91-103
15. Fujimoto N., et al. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin. Chim. Acta 231 1 (1994) 79-88
16. Green L.C. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal. Biochem. 126 (1982) 131-138
17. Hadi H.A., and Suwaidi J.A. Endothelial dysfunction in diabetes mellitus. Vasc. Health Risk Manag. 3 6 (2007) 853-876
18. Hroussalas G., et al. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in overweight/obese postmenopausal women. Maturitas 59 4 (2008) 339-349
19. Ikeda U., and Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin. Cardiol. 26 2 (2003) 55-59
20. Inokubo Y., et al. Plasma level of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 141 (2001) 211-217
21. Kowalska I., et al. Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism 51 6 (2002) 733-736
22. Lundberg J.O., and Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler. Thromb. Vasc. Biol. 25 5 (2005) 915-922
23. Matthews J.N., et al. Analysis of serial measurements in medical research. BMJ 300 (1990) 230-235
24. Milicevic Z., et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 31 Suppl 2 (2008) S155-S160
25. Panza J.A., et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 323 (1990) 22-27
26. Petersen J.L., and McGuire D.K. Impaired glucose tolerance and impaired fasting glucose-a review of diagnosis, clinical implications and management. Diabet. Vasc. Dis. Res. 2 1 (2005) 9-15
27. Raffetto J.D., and Khalil. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75 2 (2008) 346-359
28. Sierevogel M.J., et al. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr. Pharm. Des. 9 13 (2003) 1033-1040
29. Spranger J., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361 9353 (2003) 226-228
30. Stirban A.O., and Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care 31 Suppl 2 (2008) S215-221
31. Yamauchi T., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001) 941-946
32. Winer B.J. Statistical principles in experimental design. 2nd ed (1971), McGraw-Hill, New York
33. World Health Organization. Obesity: preventing and managing the global epidemic. report of WHO consultation on obesity (1997), Geneva, WHO